CYBERMED NEWS - Higher Medical Scientifc Information and Research

BIOTECHNOLOGY

COVID 19: Halix ready for vaccine production

Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford . Dutch CDMO HALIX B.V. has joined a research consortium coordinated by the University of Oxford,...

Mobidiag’s COVID-19 test okayed for emergency use

Molecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.

COVID-19: Solnatide approved for compassionate use

Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico's solnatide. The more COVID-19 patients reach advanced disease...

Apeptico gets EU grant for COVID-19 drug

Austrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients According to the Viennese company, 20% of hospitalised...

Novacyt inks contract on Covid-19 diagnostics

Paris-based Novacyt SA has signed a global distribution agreement with Bruker Ltd for its COVID-19 diagnostic test. Novacyt SA ’s British molecular diagnostics division Primerdesign Ltd (Camberley) signed a...

BioNTech SE’s COVID-19 vaccine attracts investment

Chinese Fosun Pharma Ltd has made the largest investment in a foreign company for a COVID-19 vaccine development: BioNTech’d mRNA vaccine BNT162. Under the deal, Chinese Fosun Pharmaceutical (Group)...

Wuxi Biologics and Vir Biotechnology announce mAbs development collaboration to...

Chinese CDMO WuXi Biologics has linked up with San Francisco biotech firm Vir Biotechnology to develop and manufacture human monoclonal antibodies (mAbs) to potentially treat coronavirus disease (COVID-19), the two...

MercachemSyncom, Bionetix, and ProQinase ink AML contract

Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing

iOnctura SA bags €15m in Series A round

Merck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3Kδ inhibitor and autotaxin inhibitor to the clinic.
Indietro123Avanti
Biotechnology : nature.com


Utilizziamo i cookie sul nostro sito Web. Alcuni di essi sono essenziali per il funzionamento del sito, mentre altri ci aiutano a migliorare questo sito e l'esperienza dell'utente (cookie di tracciamento). Puoi decidere tu stesso se consentire o meno i cookie. Ti preghiamo di notare che se li rifiuti, potresti non essere in grado di utilizzare tutte le funzionalità del sito.